Skip to main content

Headlands Research Accelerates Growth and Diversity Commitment with the Acquisition of Multi-Site Southern California Based Artemis Institute for Clinical Research

Written by Customer Service on . Posted in Mergers And Acquisitions.

SAN FRANCISCO, Feb. 17, 2021 (GLOBE NEWSWIRE) — Headlands Research (www.headlandsresearch.com), a global next-generation clinical research site organization, today announced that it has acquired Artemis Institute for Clinical Research. The acquisition significantly strengthens Headlands’ ability to profoundly impact the clinical trials process and elevates its global footprint to 13 clinical trial sites.
“Artemis brings a highly experienced and talented research team who cover a wide range of therapeutic areas that align with several of our Centers of Excellence, including Psychiatry, Neurology, and Vaccine trials,” said Mark Blumling, CEO and Founder of Headlands Research. “We believe Artemis’ expertise complements Headlands’ global portfolio of clinical trial research competencies, and of equal importance, further builds upon our significant commitment to diversity in clinical trial enrollment.”Artemis Institute for Clinical Research was founded by Dr. Vishaal Mehra in 2008 with the purpose of prioritizing patients and advancing medicine. With locations in San Diego and Riverside, Artemis specializes in the areas of Psychiatry, Neurology, Vaccine, Inpatient, and Medical Device clinical trials. To date, Artemis has conducted over 500 clinical trials across 20 therapeutic areas.“We are very excited to be joining Headlands Research and we share in their vision to dramatically improve the clinical trial process,” said Dr. Vishaal Mehra, CEO and founder of Artemis Institute for Clinicals Research. “We are impressed with the leadership, innovation and growth trajectory of Headlands Research and believe that together we can continue to expand our research efforts in Southern California.”About Headlands Research
Headlands Research was founded on the idea that clinical trial research needs to significantly evolve to better match the current healthcare climate, as well as the real-world needs of patients. Its mission is to profoundly change the clinical process through a platform of best-in-class research facilities that gather high-quality data thrd ough increased trial participation while addressing specialty populations that are underserved. Based in San Francisco and backed by KKR, Headlands aims to ensure that high-quality therapeutics are made available to patients who can benefit from them. Additional information about the company is available at www.headlandsresearch.com.About KKR
KKR is a leading global investment firm that manages multiple alternative asset classes, including private equity, energy, infrastructure, real estate and credit, with strategic partners that manage hedge funds. The investment in Headlands is being funded through KKR’s Health Care Strategic Growth Fund. KKR aims to generate attractive investment returns for its fund investors by following a patient and disciplined investment approach, employing world-class people, and driving growth and value creation with KKR portfolio companies. KKR invests its own capital alongside the capital it manages for fund investors and provides financing solutions and investment opportunities through its capital markets business. References to KKR’s investments may include the activities of its sponsored funds. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR’s website at www.kkr.com.Media Contact:
Christian Sebastian
Headlands Research
media@headlandsresearch.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.